Ruboxistaurin
- Generic Name
- Ruboxistaurin
- Drug Type
- Small Molecule
- Chemical Formula
- C28H28N4O3
- CAS Number
- 169939-94-0
- Unique Ingredient Identifier
- 721809WQCP
- Background
Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.
Effect of Ruboxistaurin on Clinically Significant Macular Edema
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT00133952
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 731
- Registration Number
- NCT00090519
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
- Conditions
- Diabetes Mellitus, Non-Insulin-DependentDiabetes Mellitus, Insulin-DependentDiabetic Neuropathies
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00044408
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
Treatment of Peripheral Neuropathy in Patients With Diabetes
- Conditions
- Diabetic NeuropathiesDiabetes Mellitus
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT00044421
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
πͺπΈFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dos Hermanas, Sevilla, Spain
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
- Conditions
- Diabetic NeuropathiesDiabetes Mellitus, Insulin-DependentDiabetes Mellitus, Non-Insulin-Dependent
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00044395
- Locations
- πͺπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.